November 2008

Blood testing plays a critical role in diagnosis and treatment of chronic myeloid leukemia (CML).

A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis' novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC). NSCLC is the most prevalent cause of cancer death among men and women in the United States and globally.

The International Liver Cancer Association (ILCA) takes a multidisciplinary approach to furthering the understanding and management of hepatocellular carcinoma (HCC). In September 2008, researchers from more than 40 countries attended the Second Annual Conference in Chicago, Illinois to discuss the most recent findings on diagnosis and treatment.

Reporting on ASCO's October 2008 Breast Cancer Symposium and the Second Annual Conference of the International Liver Cancer Association held in September, highlighting new research and emerging trends in patient care and treatments.

Key findings from the 2008 ASCO Breast Cancer Conference focus on the latest multidisciplinary research as well as in-depth discussions on how and when to translate new findings into patient care. Highlighted presentations address the need for greater selectivity in choosing a therapy regimen for a specific patient with breast cancer. In particular, what efforts are underway to develop targeted treatments for triple-negative breast tumors?